JP2018530574A5 - - Google Patents

Download PDF

Info

Publication number
JP2018530574A5
JP2018530574A5 JP2018518654A JP2018518654A JP2018530574A5 JP 2018530574 A5 JP2018530574 A5 JP 2018530574A5 JP 2018518654 A JP2018518654 A JP 2018518654A JP 2018518654 A JP2018518654 A JP 2018518654A JP 2018530574 A5 JP2018530574 A5 JP 2018530574A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
antibody
composition according
antigen
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018518654A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018530574A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/055794 external-priority patent/WO2017062649A1/en
Publication of JP2018530574A publication Critical patent/JP2018530574A/ja
Publication of JP2018530574A5 publication Critical patent/JP2018530574A5/ja
Pending legal-status Critical Current

Links

JP2018518654A 2015-10-07 2016-10-06 患者の加齢黄斑変性を治療する方法 Pending JP2018530574A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562238483P 2015-10-07 2015-10-07
US62/238,483 2015-10-07
PCT/US2016/055794 WO2017062649A1 (en) 2015-10-07 2016-10-06 A method for treating age-related macular degeneration in a patient

Publications (2)

Publication Number Publication Date
JP2018530574A JP2018530574A (ja) 2018-10-18
JP2018530574A5 true JP2018530574A5 (enExample) 2019-11-14

Family

ID=57200105

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018518654A Pending JP2018530574A (ja) 2015-10-07 2016-10-06 患者の加齢黄斑変性を治療する方法

Country Status (4)

Country Link
US (1) US11203634B2 (enExample)
EP (1) EP3359566A1 (enExample)
JP (1) JP2018530574A (enExample)
WO (1) WO2017062649A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL263481B2 (en) 2016-06-14 2024-06-01 Regeneron Pharma Anti-c5 antibodies and uses thereof
AU2018383751B2 (en) 2017-12-13 2025-05-08 Regeneron Pharmaceuticals, Inc. Anti-C5 antibody combinations and uses thereof
US20190247560A1 (en) 2018-02-13 2019-08-15 Gambro Lundia Ab Extracorporeal devices and methods of treating complement factor related diseases
GB201905810D0 (en) * 2019-04-25 2019-06-05 Volution Immuno Pharmaceuticals Sa Method of treatment
CN113754763B (zh) * 2020-06-05 2024-03-08 天辰生物医药(苏州)有限公司 分离的抗原结合蛋白及其用途
EP4397306A1 (en) * 2023-01-05 2024-07-10 Dompe' Farmaceutici S.P.A. C5ar1 inhibitors for use in the treatment of ocular mucous membrane pemphigoid and/or oral mucous membrane pemphigoid
WO2024238867A1 (en) * 2023-05-16 2024-11-21 Regenxbio Inc. Vectorized anti-complement antibodies and administration thereof
EP4761750A1 (en) * 2023-08-17 2026-06-24 Innovent Biologics (Suzhou) Co., Ltd. Methods of treating age-related macular degeneration and diabetic macular edema

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US5258498A (en) 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
US5525491A (en) 1991-02-27 1996-06-11 Creative Biomolecules, Inc. Serine-rich peptide linkers
EP0512733A2 (en) 1991-05-03 1992-11-11 Washington University Modified complement system regulator
CA2372813A1 (en) 1992-02-06 1993-08-19 L.L. Houston Biosynthetic binding protein for cancer marker
US6005079A (en) 1992-08-21 1999-12-21 Vrije Universiteit Brussels Immunoglobulins devoid of light chains
DE69334275D1 (de) 1992-08-21 2009-05-20 Univ Bruxelles Immunoglobuline ohne Leichtkette
WO1994025591A1 (en) 1993-04-29 1994-11-10 Unilever N.V. PRODUCTION OF ANTIBODIES OR (FUNCTIONALIZED) FRAGMENTS THEREOF DERIVED FROM HEAVY CHAIN IMMUNOGLOBULINS OF $i(CAMELIDAE)
US6074642A (en) 1994-05-02 2000-06-13 Alexion Pharmaceuticals, Inc. Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
CA2326389C (en) 1998-04-21 2007-01-23 Micromet Gesellschaft Fur Biomedizinische Forschung Mbh Novel cd19xcd3 specific polypeptides and uses thereof
ITMI20021527A1 (it) 2002-07-11 2004-01-12 Consiglio Nazionale Ricerche Anticorpi anti componente c5 del complemento e loro uso
US9415102B2 (en) 2002-09-06 2016-08-16 Alexion Pharmaceuticals, Inc. High concentration formulations of anti-C5 antibodies
US8454963B2 (en) 2003-11-13 2013-06-04 Musc Foundation For Research Development Tissue targeted complement modulators
JP5838021B2 (ja) 2005-04-15 2015-12-24 マクロジェニクス，インコーポレーテッド 共有結合型ダイアボディとその使用
KR20140053410A (ko) 2005-08-19 2014-05-07 아보트 러보러터리즈 이원 가변 도메인 면역글로불린 및 이의 용도
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
JP5405122B2 (ja) 2005-12-21 2014-02-05 ワイス・エルエルシー 低粘度のタンパク質製剤およびその用途
HUE066795T2 (hu) 2006-03-15 2024-09-28 Alexion Pharma Inc Paroxysmalis nocturnalis haemoglobinuriában szenvedõ betegek kezelése egy komplement inhibitorral
PY09026846A (es) * 2008-08-05 2015-09-01 Novartis Ag Composiciones y métodos para anticuerpos que se dirigen a la proteína de complemento c5
AU2011245117B2 (en) * 2010-04-30 2015-03-12 Alexion Pharmaceuticals, Inc. Anti-C5a antibodies and methods for using the antibodies
TW201241008A (en) 2010-10-01 2012-10-16 Alexion Pharma Inc Polypeptides that bind to human complement component C5
TWI622597B (zh) 2011-03-28 2018-05-01 賽諾菲公司 具有交叉結合區定向之雙重可變區類抗體結合蛋白
NZ711451A (en) * 2014-03-07 2016-05-27 Alexion Pharma Inc Anti-c5 antibodies having improved pharmacokinetics

Similar Documents

Publication Publication Date Title
AU2025271125A1 (en) Methods for treating or preventing ophthalmological conditions
JP2025004075A (ja) 眼疾患を処置する方法
ES2968255T3 (es) Anticuerpos anti-péptidos beta amiloides N3-beta-glu y usos de los mismos
JP2016528247A5 (enExample)
JP2017042172A5 (enExample)
JP2010528047A5 (enExample)
WO2008154251A4 (en) C3b antibodies and methods for the prevention and treatment of complement- associated disorders
JP2017515811A5 (enExample)
RU2009147744A (ru) Профилактика и лечение патологических состояний глаз, вызванных комплементом
CN117024583A (zh) 抗N3pGlu淀粉状蛋白β肽抗体及其用途
JP2011504872A5 (enExample)
EA201000787A1 (ru) Антигенсвязывающие белки
JP2015503909A5 (enExample)
JP2018505882A5 (enExample)
BR112019018950A2 (pt) métodos para tratamento de doenças e distúrbios mediados por complemento
RU2018119014A (ru) АНТИТЕЛА ПРОТИВ Нtr1 И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
NZ585110A (en) Method and compositions for diagnosis and treatment of amyloidosis
JP2019510078A5 (enExample)
EA017945B1 (ru) Композиции и способы лечения и профилактики состояний фиброза, воспаления и неоваскуляризации глаза животного
US11732046B2 (en) Modified anti-PD-L1 antibody and methods and uses for treating a neurodegenerative disease
JP2018529661A5 (enExample)
ES2855973T3 (es) Nuevo anticuerpo útil en trastornos neurológicos o neurodegenerativos
JP2018512402A5 (enExample)
JP2009519025A5 (enExample)
EP4251204A1 (en) Vegf antagonist for use in methods for treating ocular diseases